MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) ...

Announced in early January 2025, ProMIS initiated PRECISE-AD based on the encouraging results from the Phase 1a trial of PMN310 and has since completed enrollment of the first cohort of patients and ...

SATURDAY, May 3, 2025 (HealthDay News) — Amyotrophic lateral sclerosis (ALS) – known as Lou Gehrig’s Disease based on the ...

The approved ALS therapy Radicava may cause serious unexpected side effects, such as liver problems and blood clots, per U.S.

Within a couple hours, the bride was doing the limbo under Eby’s walker, and Eby was giving people walker rides all over the ...

In neurodegenerative diseases such as Alzheimer's or Parkinson's, proteins accumulate in the body's cells, fold incorrectly ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...